Literature DB >> 21884703

Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo.

Friedrich Felix Hoyer1, Martin Steinmetz, Sebastian Zimmer, Astrid Becker, Dieter Lütjohann, Rainer Buchalla, Andreas Zimmer, Georg Nickenig.   

Abstract

Low-dose oral tetrahydrocannabinol (THC) reduces progression of atherosclerosis in mice. THC activates central cannabinoid-1 receptors (CB1) with subsequent psychoactive effects as well as peripheral cannabinoid-2 receptors (CB2). In order to dissect the underlying mechanisms, we performed experiments under selective CB2 stimulation as well as after genetic disruption of the CB2 receptor. Atherosclerosis prone apolipoprotein E-deficient mice were crossed with cannabinoid receptor-2 deficient mice to obtain ApoE -/- CB2 -/- double knockout mice. After 8weeks of a high-cholesterol diet, immunohistochemical stainings of the aortic root revealed that vascular leukocyte infiltration in atherosclerotic plaques was accelerated in ApoE -/- CB2 -/- mice compared with ApoE -/- mice. This was accompanied by increased release of reactive oxygen species as measured using L012-enhanced chemiluminescence, and by decreased endothelial function as assessed in isolated aortic rings in organ chamber experiments. ApoE -/- mice treated with the selective CB2 agonist JWH 133 during a high-cholesterol diet showed decreased atherosclerotic lesion formation, improved endothelial function and reduced levels of reactive oxygen species. To assess whether CB2 expression in circulating cells influences atherosclerosis, irradiated ApoE -/- mice were repopulated with bone marrow-derived cells from ApoE -/- and ApoE -/- CB2 -/- mice and were fed a high-cholesterol diet for 8weeks. CB2 deficiency in bone marrow-derived cells increased leukocyte infiltration into the vessel wall, but had no impact on plaque formation. Cell culture experiments revealed that CB2 activation diminishes ROS generation in vascular cells. Selective CB2 receptor stimulation modulates atherogenesis via impact on both circulating proinflammatory and vascular cells. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21884703     DOI: 10.1016/j.yjmcc.2011.08.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  21 in total

Review 1.  The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.

Authors:  Makenzie L Fulmer; Douglas P Thewke
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2018

2.  Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.

Authors:  Sabine Steffens; Pál Pacher
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction.

Authors:  Rebecca Hartzell Robinson; Joseph J Meissler; Jessica M Breslow-Deckman; John Gaughan; Martin W Adler; Toby K Eisenstein
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-04       Impact factor: 4.147

4.  Cannabinoid receptor CB2 protects against balloon-induced neointima formation.

Authors:  Filippo Molica; Christian M Matter; Fabienne Burger; Graziano Pelli; Sébastien Lenglet; Andreas Zimmer; Pal Pacher; Sabine Steffens
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-06       Impact factor: 4.733

5.  Pharmacological Properties of the Plant-Derived Natural products Cannabinoids and Implications for Cardiovascular Health.

Authors:  Luca Liberale; Fabrizio Montecucco; Federico Carbone
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 7.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Authors:  Roger G Pertwee
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

8.  Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice.

Authors:  Courtney Netherland-Van Dyke; Ward Rodgers; Makenzie Fulmer; Zachary Lahr; Douglas Thewke
Journal:  J Cardiol Ther       Date:  2015-07

Review 9.  Downstream effects of endocannabinoid on blood cells: implications for health and disease.

Authors:  Valeria Gasperi; Daniela Evangelista; Isabella Savini; Domenico Del Principe; Luciana Avigliano; Mauro Maccarrone; Maria Valeria Catani
Journal:  Cell Mol Life Sci       Date:  2015-05-10       Impact factor: 9.261

10.  Direct activation of Ca2+ and voltage-gated potassium channels of large conductance by anandamide in endothelial cells does not support the presence of endothelial atypical cannabinoid receptor.

Authors:  Alexander I Bondarenko; Olga Panasiuk; Iryna Okhai; Fabrizio Montecucco; Karim J Brandt; Francois Mach
Journal:  Eur J Pharmacol       Date:  2017-03-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.